GlassScriptPhysician profile
Frank A Koroluk
NPI 1669479143
$4,445.27
in general payments reported to CMS, 2019-2025
35 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $731 · 2023: $1,310 · 2024: $1,079 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522 · Education: $31.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.20 |
| Education | $31.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $838.86 | 2022-2025 | |
| Amgen INC. | $523.93 | 2021-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $500.95 | 2021-2025 | Lifevest |
| Pfizer INC. | $342.32 | 2022-2025 | |
| Boston Scientific Corporation | $222.08 | 2022-2025 | Bodyguardian, Watchman Access System, Cds - Mct/Cem Monitoring |
| Corcept Therapeutics | $204.77 | 2023-2025 | Korlym |
| Lilly USA, LLC | $190.24 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $187.80 | 2023-2024 | Veklury |
| Merck Sharp & Dohme LLC | $166.70 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Alnylam Pharmaceuticals INC. | $164.96 | 2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $150.25 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $108.24 | 2021-2023 | Cresemba |
| Philips North America LLC | $86.85 | 2022-2024 | (5091) Amb Mon & Diag Und |
| Abbott Laboratories | $75.06 | 2023-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Halozyme INC | $73.13 | 2023 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Koroluk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.